Login
$ZLAB
$23.47 -$1.13 (4.59%) Live

Company Executives

Officer Age In this role Joined 2025 pay Source
Samantha (Ying) Du Also a director
Founder, Chief Executive Officer, Chairperson of the Board of Directors
61 Not stated Not stated $10,677,221
Yajing Chen
Chief Financial Officer
58 Since 2023
3 years
Not stated $3,185,488
Josh Smiley
President and Chief Operating Officer
56 Not stated Not stated Not reported
F. Ty Edmondson
Chief Legal Officer
60 Since 2020
6 years
2020 Not reported
Frazor Titus Edmondson III
Chief Legal Officer
Title from the Form 4 dated Jun 25, 2026
Not stated Not stated Not stated Not reported
Rafael G. Amado
President, Head of Global Research and Development
62 Since 2024
2 years
2022 $4,010,205
Yizhe Wang
Operating Partner
Title from the Form 4 dated May 11, 2026
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
9
serving now
Independent
7 of 9
stated in the proxy
Average tenure
7.7 years
from year joined
CEO also chairs the board
Yes
Samantha (Ying) Du
Director Age On board Independent Committees Other public boards 2025 pay Source
Samantha (Ying) Du
61 2014
12 years
Not independent
Research and Development
None stated Paid as CEO
John David Diekman
83 2017
9 years
Independent None stated None stated $513,614
Richard Brian Gaynor
76 2021
5 years
Independent None stated Alkermes plc (NASDAQ) $465,940
Nisa Bernice Wing-Yu Leung
55 2014
12 years
Independent None stated None stated $448,497
William David Lis
61 2018
8 years
Independent
Audit
None stated $456,114
Scott William Morrison
68 2021
5 years
Independent None stated IDEAYA Biosciences Inc. (NASDAQ), Tarsus Pharmaceuticals, Inc. (NASDAQ), Vera Therapeutics, Inc. (NASDAQ) $474,989
Leon Oliver Moulder, Jr.
68 2020
6 years
Not independent
Commercial
Dianthus Therapeutics, Inc. (NASDAQ) $479,739
Michel Pericles Vounatsos
64 2023
3 years
Independent None stated Revvity, Inc. (NYSE) $472,965
Peter Karl Wirth
75 2017
9 years
Independent None stated None stated $482,489

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Apr 28, 2026
Mr. Moulder
One of the members of the Company’s Board of Directors; Chief Executive Officer and Chairman of the Board of Directors of Zenas
Amount not stated
Since January 2025

License agreement under which the Company obtained a license under patents and know-how of Zenas to develop and commercialize products targeting IGF-1R in Greater China; upfront fee paid and additional milestone and royalty payments possible.

With Zenas BioPharma (HK) Limited Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support